ANDA 65242, held by Lannett. Clindamycin Hydrochloride.
As of Nov 16, 2026, ANDA 65242 (Clindamycin Hydrochloride), held by Lannett, was first approved by FDA on Aug 12, 2005, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 12, 2005 | Original application | Approved | None posted |
| Clindamycin HydrochlorideEQ 75MG BASE · capsule;oral | Clindamycin Hydrochloride | Rx |
| Clindamycin HydrochlorideEQ 150MG BASE · capsule;oral | Clindamycin Hydrochloride | Rx |
| Jul 24, 2017 | Supplement 21Labeling · Standard review | Approved | None posted |
| Mar 24, 2017 | Supplement 16Labeling · Standard review | Approved | None posted |
| Mar 24, 2017 | Supplement 20Labeling · Standard review | Approved | None posted |
| Dec 21, 2014 | Supplement 15Labeling · Standard review | Approved | None posted |
| Aug 25, 2014 | Supplement 5Labeling | Approved | None posted |
| Aug 22, 2014 | Supplement 2Labeling | Approved | None posted |
| Dec 20, 2011 | Supplement 12Labeling | Approved | None posted |
| Dec 22, 2010 | Supplement 11Labeling | Approved | None posted |
| Jun 8, 2007 | Supplement 6Labeling | Approved | None posted |
| Aug 12, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters